Premium
Uremic Toxin Indoxyl Sulfate Inhibits Human Vascular Smooth Muscle Cell Proliferation
Author(s) -
Mozar Anaïs,
Louvet Loïc,
Morlière Patrice,
Godin Corinne,
Boudot Cédric,
Kamel Saïd,
Drüeke Tilman B,
Massy Ziad A
Publication year - 2011
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2010.00885.x
Subject(s) - uremic toxins , toxin , vascular smooth muscle , intracellular , in vivo , cell growth , medicine , sulfate , in vitro , pharmacology , biochemistry , endocrinology , smooth muscle , biology , chemistry , kidney disease , microbiology and biotechnology , organic chemistry
Uremic syndrome is attributed to the progressive retention of a large number of compounds, such as indoxyl sulfate, which under physiological conditions are excreted by the kidneys. Previous in vitro studies have demonstrated that uremic indoxyl sulfate concentrations induce a weak increase in the proliferation of both rat and human vascular aortic smooth muscle cells (hVASMC) after short term exposition to the toxin (i.e. 24 h). In the present study, we evaluated indoxyl sulfate effects on the proliferation of hVASMC at three different concentrations after long‐term exposure (seven days). In contrast to previously published studies, we observed a dose‐dependent and significant inhibitory effect of this toxin on hVASMC proliferation. We also demonstrated that indoxyl sulfate inhibits epidermal growth factor‐induced hVASMC proliferation after long‐term exposure. Indoxyl sulfate effects were associated with a dose‐dependent induction of intracellular reactive oxygen species and up‐regulation of p21 and p27 protein expression. Chronic exposure to indoxyl sulfate produces a significant inhibitory effect on hVASMC proliferation. The relevance of these findings must be evaluated by further studies, particularly in an in vivo setting.